Evidence map›Paper›PMID 36985905›Full record

ReviewNanomaterials (Basel, Switzerland)2023

Recent Advances in Metal-Based NanoEnhancers for Particle Therapy.

Yao-Chen Chuang, Ping-Hsiu Wu, Yao-An Shen, Chia-Chun Kuo, Wei-Jun Wang, Yu-Chen Chen, Hsin-Lun Lee, Jeng-Fong Chiou

Open access · goldAbstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yao-Chen ChuangDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.ORCID 0000-0001-9595-1201
Ping-Hsiu WuDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
Yao-An ShenDepartment of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan.ORCID 0000-0002-4393-2794
Chia-Chun KuoDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
Wei-Jun WangDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.ORCID 0000-0002-9371-1025
Yu-Chen ChenDepartment of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan.
Hsin-Lun LeeDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
Jeng-Fong ChiouDepartment of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
Taipei Medical University Hospital · TWTaipei Medical University · TW

Funding

Ministry of Science and Technology of the People's Republic of China 109-2314-B-038-021-MY3Ministry of Science and Technology of the People's Republic of China 111-2314-B-038-087National Science and Technology Council 111-2622-B-038-008
6 · The paper itself

Abstract

Radiotherapy is one of the most common therapeutic regimens for cancer treatment. Over the past decade, proton therapy (PT) has emerged as an advanced type of radiotherapy (RT) that uses proton beams instead of conventional photon RT. Both PT and carbon-ion beam therapy (CIBT) exhibit excellent therapeutic results because of the physical characteristics of the resulting Bragg peaks, which has been exploited for cancer treatment in medical centers worldwide. Although particle therapies show significant advantages to photon RT by minimizing the radiation damage to normal tissue after the tumors, they still cause damage to normal tissue before the tumor. Since the physical mechanisms are different from particle therapy and photon RT, efforts have been made to ameliorate these effects by combining nanomaterials and particle therapies to improve tumor targeting by concentrating the radiation effects. Metallic nanoparticles (MNPs) exhibit many unique properties, such as strong X-ray absorption cross-sections and catalytic activity, and they are considered nano-radioenhancers (NREs) for RT. In this review, we systematically summarize the putative mechanisms involved in NRE-induced radioenhancement in particle therapy and the experimental results in in vitro and in vivo models. We also discuss the potential of translating preclinical metal-based NP-enhanced particle therapy studies into clinical practice using examples of several metal-based NREs, such as SPION, Abraxane, AGuIX, and NBTXR3. Furthermore, the future challenges and development of NREs for PT are presented for clinical translation. Finally, we propose a roadmap to pursue future studies to strengthen the interplay of particle therapy and nanomedicine.

Indexed as

nanomedicinenanoparticlesparticle therapyproton therapyradioresistanceradiosensitizationtheranostic

Identifiers

PMID36985905
PMCPMC10056155
OpenAlexW4324067687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.